Xia L, Shen T, Dong W, et al
By dampening the overzealous cardiac response and providing a steadying hand to a racing heart, beta blockers may help patients reclaim a sense of normalcy and engage more fully in daily life activities
GLP-1 RAs under development for NASH Semaglutide Semaglutide showed a significant dose-dependent NASH resolution without worsening of fibrosis in a phase 2 randomized controlled trial (RCT) involving patients with NASH and stage 13 fibrosis
Liraglutide or placebo was administered daily, starting at 0.6 mg and increasing to 3.0 mg or the highest tolerated dose
Perjeta (pertuzumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.11 billion Why it sold so well: Roches Perjeta generated global sales of CHF 3.62 billion ($4.11 billion) last year, maintaining its position as a key therapy in HER2-positive breast cancer
regulation of metabolic pathways calcium homeostasis remodeling of cytoskeleton inflammation protein folding Other Vital Roles of glutathione (GSH) include
